Jason Fontenot, PhD, on Reducing the Need for Immunosuppression in Renal Transplantation

Video

The chief scientific officer of Sangamo Therapeutics discussed the first-in-human STEADFAST trial.

“[The STEADFAST trial] has a lot of potential because there are some real problems with the systemic immune suppression used to treat most transplants. It's also the first stepping stone for using regulatory T-cells as a therapy for many other autoimmune diseases. In that way, it's a proof of concept.”

A first-in-human trial (NCT04817774) is evaluating the chimeric antigen receptor regulatory T-cell (CAR-Treg) therapy TX200-TR101 (Sangamo Therapeutics) in achieving allograft acceptance in patients with end-stage renal disease after HLA-A02-mismatched renal transplantation.

An overview of the study, which has dosed its first participant, was presented by Katharina H. Schreeb, MD, PhD, head of autoimmune and oncology, Sangamo Therapeutics, at the American Society of Gene & Cell Therapy 25th Annual Meeting (ASGCT), held in Washington, DC, and virtually May 16-19, 2022.

CGTLive spoke with Jason Fontenot, PhD, senior vice president and chief scientific officer, Sangamo Therapeutics, to learn more about the study and the advantages of TX200-TR101 in this setting and autoimmune diseases. He discussed the next steps for the study.

REFERENCE
Schreeb KH, Culme-Seymour E, Dumont C, Hsu B, Atkinson G. STEADFAST: A first-in-human study assessing HLA-A02-chimeric antigen receptor regulatory T cells in renal transplantation. Presented at: ASCGT 2022, May 16-19, 2022, Washington DC. Abstract #798.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Nathan Yozwiak, PhD, the head of research at the GCTI
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Related Content
© 2025 MJH Life Sciences

All rights reserved.